SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, said it promoted Dr. Vishwa Srivastava to president and appointed Gary Lo as chief financial officer. Srivastava, previously CEO of the company’s Asia Pacific operations, will focus on building the U.S. business and leading global operations. Both executives are based in the United States, according to the announcement.
The leadership changes arrive as SS Innovations advances international expansion plans for its SSi Mantra surgical robotic system. The company is responding to questions from the U.S. Food and Drug Administration regarding its 510(k) premarket notification while pursuing CE marking certification in the European Union. It is also finalizing a pipeline of additional health care technologies at its research and development facility in India, with plans to introduce them in the coming months.
Lo brings more than three decades of financial leadership experience across technology companies, including the medical technology sector, with expertise in capital markets, financial planning and strategic growth. His appointment comes at a critical juncture for a company that must fund regulatory efforts and commercial expansion. Srivastava’s promotion signals a sharper focus on the U.S. market, where FDA clearance would open access to one of the world’s largest surgical device markets.
The SSi Mantra system is a modular, multi-arm robotic platform with 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for patient-related information, a virtual real-time image of the robotic patient side arm carts, and the ability to superimpose 3D models of diagnostic imaging. An optional SSi MantrAsana tele-surgeon console is designed as a portable, compact alternative to the standard command center, offering equivalent control functionality with enhanced portability, ergonomic flexibility and telesurgery capability. The system uses over 40 different types of robotic endo-surgical instruments to support specialties including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to improve safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.
Headquartered in India, SS Innovations describes itself as a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly and cost-effective surgical robotic solutions. The company’s vision is to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. For investors, the dual appointments may be read as a signal that SS Innovations is preparing for the commercial and financial demands of entering regulated Western markets. The company’s ability to answer FDA questions and secure CE marking will be key milestones to watch. The full press release is available at https://nnw.fm/dX3qc, and additional information can be found at ssinnovations.com or LinkedIn. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
